Medfield Diagnostics AB (XSAT:MEDF) ROCE % : -21.11% (As of Sep. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Medfield Diagnostics AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medfield Diagnostics AB's annualized ROCE % for the quarter that ended in Sep. 2023 was -21.11%.

Medfield Diagnostics AB ROCE % Historical Data

The historical data trend for Medfield Diagnostics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medfield Diagnostics AB ROCE % Chart

Medfield Diagnostics AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-18.49

-17.15

-13.64

-12.58

-12.32

Medfield Diagnostics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-10.20	-14.10	-12.27	-18.60	-21.11

Medfield Diagnostics AB ROCE % Calculation

Medfield Diagnostics AB's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-8.369	/	( ( (66.989 - 3.686)	+	(76.63 - 4.029) )	/ 2 )
	=	-8.369	/	( (63.303	+	72.601)	/ 2 )
	=	-8.369	/	67.952
	=	-12.32 %

Medfield Diagnostics AB's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-15.22	/	( ( (71.666 - 4.459)	+	(80.663 - 3.662) )	/ 2 )
	=	-15.22	/	( ( 67.207	+	77.001 )	/ 2 )
	=	-15.22	/	72.104
	=	-21.11 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Medfield Diagnostics AB (XSAT:MEDF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medfield Diagnostics AB ROCE % Related Terms

Thank you for viewing the detailed overview of Medfield Diagnostics AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medfield Diagnostics AB (XSAT:MEDF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medfield Diagnostics AB (XSAT:MEDF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Medicinaregatan 8B, Gothenburg, SWE, 413 90

Website

http://www.medfielddiagnostics.com

Medfield Diagnostics AB develops, markets and sells diagnostic instrumentation based on microwave technology. The company researches the use of microwave technology in stroke diagnostics. Its products consist of Strokefinder and Impending Applications.

Medfield Diagnostics AB (XSAT:MEDF) Headlines

No Headlines